Insider Sales, Buy Ratings, and AI Momentum: BioNTech, Evotec, and Vidac Pharma in Focus

Vidac Pharma: Insider Sales Present Buying Opportunity

In recent weeks, there have been numerous insider sales at Vidac Pharma. What is generally a negative sign is, in this case, a buying opportunity for investors. This is because the biotech company will benefit directly from the sales. Management had previously announced its intention to sell shares in order to make the net proceeds directly available to the company for financing. This is intended to accelerate development in the current year. The market seems to be slowly realizing this.

After the stock lost about 17% of its value at the start of the insider sales, it has since stabilized between EUR 0.55 and EUR 0.60. This appears to present an exciting buying opportunity. In the fight against cancer, the biotech company aims to reach important milestones this year. Analysts at Sphene Capital estimate the fair value of Vidac shares at EUR 4.20. Given its market capitalization of just EUR 30 million, the oncology specialist is also a potential takeover candidate.

This year, Vidac has already reported positive results for its most promising drug candidate, VDA-1102. As part of a "compassionate use" program, a young girl with a tumor in the central nervous system (recurrent ependymoma) was treated with VDA-1102. The drug was administered before and after the third brain surgery. The goal was to regulate the tumor's metabolic activity so that the surgery and subsequent radiation therapy would be more effective. The surgery and radiation therapy were successful. Vidac reported that the metabolic stabilization achieved by VDA-1102 may have supported the entire therapeutic process. VDA-1102 is actually being developed for the treatment of skin cancer.

However, the case described suggests that Vidac's approach could have broader implications for cancer treatment. The company aims to address the disrupted metabolism of cancer cells. By targeting the so-called "Warburg effect," tumor cells may be deprived of key energy pathways, which could contribute to normalization or programmed cell death. If this approach is supported by further clinical data, the stock could offer significant upside potential from current levels.

BioNTech: Analysts Praise

Is BioNTech back on track for success? The stock of Germany's largest biotech company has gained just over 15% in the past two weeks. The stock is trading again at around EUR 88, returning to the level seen before the surprise announcement of the founding couple's impending departure.

According to Berenberg, the stock has even more upside potential. Analysts recommend buying BioNTech with a price target of USD 155. Following the positive Phase II data in second-line therapy for uterine cancer, attention is once again turning to the biotech company's pipeline. And as is well known, the company maintains a broad clinical pipeline across multiple indications.

Analysts are citing BioNTech's announcement of promising results for a new drug to treat uterine cancer. In a study involving patients whose disease had returned after initial treatment, the drug proved highly effective. Nearly half of the participants responded positively to the therapy, with the drug working across all different groups. These results represent significant progress, as there are currently few effective treatment options for this form of cancer, and the need for new solutions for affected women is very high.

In addition to its high efficacy, the drug proved to be well-tolerated, with side effects that were mostly mild and easily managed medically. Since the data significantly exceed the previous standard, the drug is already in a larger, final trial phase. Based on these successes, BioNTech plans to apply for official approval of the drug later this year to provide patients with a new and effective treatment option as soon as possible.

Evotec: AI Potential?

Evotec has also seen a noticeable upturn recently. Over the past four weeks, the stock has risen by around 30% and is now trading at around EUR 5.60 again. In March, it had hit a multi-year low of EUR 4.

Berenberg remains bullish on this German biotech stock as well. Analysts estimate the stock's fair value at EUR 9.70 and therefore recommend buying it. The experts believe that Evotec could benefit from the use of artificial intelligence (AI) in drug discovery. With this, the analysts are alluding to the importance of the Evotec platform for data-driven drug discovery. Over the decades, Evotec has generated millions of data points from drug discovery, ranging from genomic data and imaging data to chemical libraries. Since Evotec generates this data through standardized, industrial processes in its own "wet lab," it is highly reliable. This is exactly what AI companies are desperately seeking to train their models and validate results.

Nevertheless, it must not be forgotten that Evotec is in the midst of restructuring. In the current year, the Group is expected to generate revenue of between EUR 700 million and EUR 780 million (2025: EUR 788.4 million). Adjusted EBITDA is expected to range between EUR 0 and EUR 40 million. In the weak year of 2025, it was EUR 41.1 million.

As part of the Horizon restructuring program, the company aims to save EUR 75 million in the coming years. This is expected to have a positive impact on earnings in the medium term. Evotec thus aims to increase revenue to over EUR 1 billion per year by 2030. By then, the company aims to achieve an EBITDA margin of over 20%.

Vidac Pharma's stock could offer significant upside potential if its approach to cancer therapy proves successful. Recent insider sales may unsettle some investors, but are viewed by others as a potential entry opportunity. At BioNTech, the market appears to have absorbed the impact of the founders' planned departure. The AI narrative could continue to support Evotec's stock, although it should not be overlooked that the company is undergoing restructuring. The new management has yet to fully convince the market.